Imunon, Inc. (then Celsion Corporation) — Form 10-Q summary
Reporting period: Quarter ended March 31, 2013. The filing is by Celsion Corporation, the company now identified in the request as Imunon, Inc.; the filing itself uses the Celsion name.
Business context
Celsion was a clinical-stage oncology drug developer focused on heat-activated liposomal technology. Its lead candidate, ThermoDox, was under study for primary liver cancer, colorectal liver metastases and recurrent chest-wall breast cancer. The Phase III HEAT study tested ThermoDox with radiofrequency ablation (RFA) for primary liver cancer.
Financial results and liquidity
| Metric | Q1 2013 | Q1 2012 or prior balance-sheet date |
|---|---|---|
| Licensing revenue | $125,000 | None |
| Research and development expense | $3.20 million | $4.69 million |
| General and administrative expense | $1.69 million | $1.57 million |
| Total operating expenses | $4.89 million | $6.26 million |
| Loss from operations | $4.77 million | $6.26 million |
| Net loss | $651,000 | $6.19 million |
| Net loss attributable to common shareholders | $5.25 million, including a $4.60 million noncash deemed dividend | $6.19 million |
| Basic and diluted loss per common share | $0.12 | $0.19 |
| Cash, cash equivalents and investments, including accrued interest | $45.9 million | $23.1 million at December 31, 2012 |
| Working capital | $38.7 million | $18.6 million at December 31, 2012 |
| Total liabilities | $15.7 million | $13.4 million at December 31, 2012 |
| Stockholders’ equity | $32.3 million | $12.0 million at December 31, 2012 |
Operating cash flow was positive $1.79 million, compared with negative $5.73 million a year earlier. The 2013 figure included a $4.88 million increase in deferred revenue and a $1.84 million increase in accounts payable; it should not be read as evidence of profitable operations. Investing activities used $17.20 million, primarily for investment-security purchases. Financing activities provided $20.78 million, principally from equity offerings.
The company reported approximately $5.0 million in notes payable, including a secured term loan bearing fixed interest of 11.75%, and a $57,000 equipment lease obligation. The term loan matures October 15, 2015; the company said it was complying with its covenants. There were no off-balance-sheet financing arrangements.
Material changes versus the prior period
- Net loss narrowed substantially, but results included a noncash $4.28 million gain from remeasurement of a warrant liability, compared with a $78,000 gain in Q1 2012. The liability fell from $4.28 million at year-end to $3,635 at March 31.
- R&D spending declined, mainly because HEAT study costs fell after the trial result announcement. G&A expense increased 7.6%, with the filing citing higher business-development professional fees.
- Cash and investments increased following financing transactions, including approximately $6.8 million net proceeds from common-stock sales under an at-the-market program and approximately $13.6 million net proceeds from a preferred-stock and warrant offering.
- The preferred stock was convertible into up to 12.07 million common shares, and associated warrants covered up to 6.04 million shares at $1.18 per share. By March 31, 8.02 million common shares had been issued on conversion of preferred stock.
- Hisun paid a nonrefundable $5 million development fee. It was recorded as deferred revenue and is to be recognized over the agreement’s 10-year term; $125,000 was recognized as licensing revenue in Q1.
Outlook, commentary and risks
- Clinical setback: On January 31, 2013, the company announced that ThermoDox with RFA failed to meet the HEAT study’s primary endpoint. It planned to follow patients for overall survival and conduct further analyses. Management described a post hoc subgroup signal among patients receiving RFA for at least 45 minutes, but said it remained subject to verification and review.
- Program and operating changes: In April 2013, the company deferred spending on the Phase II ABLATE study pending decisions about ThermoDox development in liver cancer, and announced a restructuring that eliminated approximately one-third of its workforce. It also engaged Cantor Fitzgerald to review potential strategic and acquisition alternatives; no transaction was assured.
- Funding: Management said significant additional capital would be needed to develop candidates through clinical development, manufacturing and commercialization. The company warned that unavailable or unfavorable financing could force delays, reductions or termination of programs, and that equity financing could dilute shareholders.
- Revenue and development risk: The company had no product sales and did not expect significant product revenue for the foreseeable future. Clinical, regulatory, manufacturing, partner-performance and commercialization uncertainties could materially affect its prospects.
- Trading and listing risk: The filing reported that the stock traded below Nasdaq’s $1.00 minimum bid price for 21 consecutive trading days through May 6, 2013; the May 8 closing bid was $1.01. Continued compliance was not assured.
- Other disclosures: The company reported no legal proceedings. Disclosure controls were deemed effective at a reasonable-assurance level, and no material change in internal control over financial reporting was identified during the quarter.
Important facts for investors to verify
- Follow-up overall-survival results and the status, validation and implications of the HEAT subgroup analysis.
- ThermoDox development plans, including the deferred ABLATE study and continued collaboration with Hisun after the HEAT result.
- Cash usage and financing needs after the quarter, including the effects of restructuring and any strategic transaction.
- Potential dilution from preferred-stock conversions, warrants, options and future equity issuance; confirm the remaining ATM capacity and any restrictions on its use.
- Nasdaq bid-price compliance and any subsequent listing notices or actions.
- Reconcile filing presentation differences: the MD&A table reports a $657,000 operating loss, while the financial statements report a $4.77 million operating loss; the statements also report R&D expense of $4.69 million for Q1 2012, while one MD&A table shows $4.96 million.